171 related articles for article (PubMed ID: 31178279)
1. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
2. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
3. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
4. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Hupe MC; Philippi C; Roth D; Kümpers C; Ribbat-Idel J; Becker F; Joerg V; Duensing S; Lubczyk VH; Kirfel J; Sailer V; Kuefer R; Merseburger AS; Perner S; Offermann A
Front Oncol; 2018; 8():623. PubMed ID: 30619757
[No Abstract] [Full Text] [Related]
5. Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.
Höflmayer D; Fraune C; Hube-Magg C; Simon R; Schroeder C; Büscheck F; Möller K; Dum D; Weidemann S; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Sauter G; Burandt E; Clauditz TS; Steurer S; Minner S; Wilczak W; Polonski A
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):e29-e38. PubMed ID: 33491944
[TBL] [Abstract][Full Text] [Related]
6. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
8. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
9. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
14. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
[TBL] [Abstract][Full Text] [Related]
15. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.
Thomas GV; Schrage MI; Rosenfelt L; Kim JH; Salur G; deKernion JB; Dorey F; Said J; Reiter RE
J Urol; 2000 Dec; 164(6):1987-91. PubMed ID: 11061897
[TBL] [Abstract][Full Text] [Related]
16. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
17. TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC.
Klapper L; Idel C; Kuppler P; Jagomast T; von Bernuth A; Bruchhage KL; Rades D; Offermann A; Kirfel J; Perner S; Ribbat-Idel J
J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743773
[TBL] [Abstract][Full Text] [Related]
18. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
20. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.
Rounbehler RJ; Berglund AE; Gerke T; Takhar MM; Awasthi S; Li W; Davicioni E; Erho NG; Ross AE; Schaeffer EM; Klein EA; Karnes RJ; Jenkins RB; Cleveland JL; Park JY; Yamoah K
Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1376-1383. PubMed ID: 30108099
[No Abstract] [Full Text] [Related]
[Next] [New Search]